

Study Number: C11297-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

C Number:

Study Gender:

PWG Approval Date

PA43: Hematology Summary

Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane

CAS Number: 25637-99-4

C11297-01

Male

See web page for date of PWG Approval

Date Report Requested: 04/26/2019

Time Report Requested: 07:40:44

Lab: Battelle

Study Number: C11297-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

PA43: Hematology Summary

Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane

CAS Number: 25637-99-4

Date Report Requested: 04/26/2019

Time Report Requested: 07:40:44

Lab: Battelle

Male: Core Males

	Phase Day	Treatment Groups (mg/kg)			
		0	0.06	0.641	6.41
Hematocrit (%)	SD 5	50.7 ± 1.8 (5)	50.8 ± 1.2 (6)	52.3 ± 2.2 (6)	50.1 ± 0.9 (6)
Percent of Control			100.2	103.1	98.8
Manual Hematocrit (%)	SD 5	49.2 ± 1.7 (5)	49.0 ± 1.0 (6)	51.3 ± 2.0 (6)	49.5 ± 0.8 (6)
Percent of Control			99.6	104.3	100.6
Hemoglobin (g/dL)	SD 5	15.2 ± 0.5 (5)	15.1 ± 0.3 (6)	15.7 ± 0.5 (6)	15.0 ± 0.3 (6)
Percent of Control			99.2	103.2	98.7
Erythrocytes (10 ⁶ /uL)	SD 5	7.71 ± 0.26 (5)	7.76 ± 0.13 (6)	7.96 ± 0.27 (6)	7.73 ± 0.13 (6)
Percent of Control			100.69	103.24	100.30
Reticulocytes (10 ³ /uL)	SD 5	441.4 ± 20.2 (5)	426.5 ± 18.8 (6)	406.8 ± 20.3 (6)	409.5 ± 13.9 (6)
Percent of Control			96.6	92.2	92.8
Nucleated Red Blood Cells (/100 WBC)	SD 5	0.00 ± 0.00 (5)	0.17 ± 0.17 (6)	0.00 ± 0.00 (6)	0.00 ± 0.00 (6)
Mean Cell Volume (fL)	SD 5	65.8 ± 0.5 (5)	65.4 ± 0.9 (6)	65.6 ± 0.9 (6)	64.8 ± 0.5 (6)
Percent of Control			99.4	99.7	98.5
Mean Cell Hemoglobin (pg)	SD 5	19.7 ± 0.1 (5)	19.4 ± 0.2 (6)	19.7 ± 0.3 (6)	19.4 ± 0.1 (6)
Percent of Control			98.5	100.1	98.4
Mean Cell Hemoglobin Concentration (g/dL)	SD 5	29.9 ± 0.2 (5)	29.7 ± 0.2 (6)	30.1 ± 0.3 (6)	29.9 ± 0.2 (6)
Percent of Control			99.3	100.5	100.0
Platelets (10 ³ /uL)	SD 5	879 ± 59 (5)	988 ± 39 (6)	927 ± 57 (6)	1048 ± 81 (6)
Percent of Control			112	105	119
White Blood Cells (10 ³ /uL)	SD 5	14.86 ± 1.15 (5)	13.48 ± 0.57 (6)	12.75 ± 0.58 (6)	13.79 ± 0.86 (6)
Percent of Control			90.68	85.78	92.81
Neutrophils (10 ³ /uL)	SD 5	1.11 ± 0.11 (5)	0.96 ± 0.06 (6)	0.94 ± 0.09 (6)	0.94 ± 0.06 (6)

Study Number: C11297-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Sprague Dawley

PA43: Hematology Summary
Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane
CAS Number: 25637-99-4

Date Report Requested: 04/26/2019
Time Report Requested: 07:40:44
Lab: Battelle

Male: Core Males

	Phase Day	Treatment Groups (mg/kg)			
		0	0.06	0.641	6.41
Percent of Control			85.88	84.68	84.08
Lymphocytes (10 ³ /uL)	SD 5	12.41 ± 0.89 (5)	11.69 ± 0.51 (6)	10.95 ± 0.42 (6)	11.93 ± 0.81 (6)
Percent of Control			94.20	88.22	96.12
Monocytes (10 ³ /uL)	SD 5	1.05 ± 0.15 (5)	0.60 ± 0.07 (6)	0.64 ± 0.13 (6)	0.66 ± 0.06 (6)
Percent of Control			57.68	60.87	62.78
Basophils (10 ³ /uL)	SD 5	0.11 ± 0.02 (5)	0.09 ± 0.01 (6)	0.09 ± 0.01 (6)	0.09 ± 0.01 (6)
Percent of Control			78.79	80.30	81.82
Eosinophils (10 ³ /uL)	SD 5	0.06 ± 0.01 (5) *	0.05 ± 0.00 (6)	0.05 ± 0.01 (6)	0.08 ± 0.02 (6)
Percent of Control			88.89	77.78	133.33
Large Unstained Cells (10 ³ /uL)	SD 5	0.12 ± 0.02 (5)	0.09 ± 0.01 (6)	0.09 ± 0.01 (6)	0.10 ± 0.01 (6)
Percent of Control			69.89	69.89	83.33

Study Number: C11297-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Sprague Dawley

PA43: Hematology Summary

Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane

CAS Number: 25637-99-4

Date Report Requested: 04/26/2019

Time Report Requested: 07:40:44

Lab: Battelle

Male: Core Males

	Phase Day	Treatment Groups (mg/kg)	
		64.1	641
Hematocrit (%)	SD 5	50.6 ± 1.0 (6)	51.2 ± 1.2 (6)
Percent of Control		99.8	100.9
Manual Hematocrit (%)	SD 5	49.3 ± 0.8 (6)	49.7 ± 1.5 (6)
Percent of Control		100.3	100.9
Hemoglobin (g/dL)	SD 5	15.2 ± 0.3 (6)	15.4 ± 0.3 (6)
Percent of Control		100.1	101.2
Erythrocytes (10 ⁶ /uL)	SD 5	7.87 ± 0.18 (6)	7.93 ± 0.18 (6)
Percent of Control		102.10	102.83
Reticulocytes (10 ³ /uL)	SD 5	401.5 ± 21.9 (6)	413.4 ± 22.2 (6)
Percent of Control		91.0	93.6
Nucleated Red Blood Cells (/100 WBC)	SD 5	0.00 ± 0.00 (6)	0.00 ± 0.00 (6)
Mean Cell Volume (fL)	SD 5	64.4 ± 0.4 (6)	64.6 ± 0.7 (6)
Percent of Control		97.8	98.2
Mean Cell Hemoglobin (pg)	SD 5	19.4 ± 0.2 (6)	19.4 ± 0.2 (6)
Percent of Control		98.2	98.3
Mean Cell Hemoglobin Concentration (g/dL)	SD 5	30.0 ± 0.2 (6)	30.1 ± 0.2 (6)
Percent of Control		100.3	100.4
Platelets (10 ³ /uL)	SD 5	852 ± 77 (6)	920 ± 44 (6)
Percent of Control		97	105
White Blood Cells (10 ³ /uL)	SD 5	12.78 ± 1.40 (6)	15.77 ± 0.76 (6)
Percent of Control		85.99	106.13
Neutrophils (10 ³ /uL)	SD 5	0.94 ± 0.10 (6)	1.21 ± 0.10 (6)

Study Number: C11297-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Sprague Dawley

PA43: Hematology Summary
Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane
CAS Number: 25637-99-4

Date Report Requested: 04/26/2019
Time Report Requested: 07:40:44
Lab: Battelle

Male: Core Males

	Phase Day	Treatment Groups (mg/kg)	
		64.1	641
Percent of Control		84.83	108.51
Lymphocytes (10 ³ /uL)	SD 5	11.05 ± 1.26 (6)	13.46 ± 0.65 (6)
Percent of Control		89.04	108.45
Monocytes (10 ³ /uL)	SD 5	0.53 ± 0.04 (6)	0.76 ± 0.15 (6)
Percent of Control		50.35	72.82
Basophils (10 ³ /uL)	SD 5	0.09 ± 0.02 (6)	0.11 ± 0.01 (6)
Percent of Control		78.79	101.52
Eosinophils (10 ³ /uL)	SD 5	0.09 ± 0.02 (6)	0.13 ± 0.06 (6)
Percent of Control		144.44	219.44
Large Unstained Cells (10 ³ /uL)	SD 5	0.09 ± 0.01 (6)	0.11 ± 0.01 (6)
Percent of Control		69.89	87.37

Study Number: C11297-01
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Sprague Dawley

PA43: Hematology Summary
Test Compound: 1,3,5,7,9,11-Hexabromocyclododecane
CAS Number: 25637-99-4

Date Report Requested: 04/26/2019
Time Report Requested: 07:40:44
Lab: Battelle

LEGEND

Values given as mean \pm SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests (unless otherwise noted).

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

**** END OF REPORT ****